Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

Michael A Via1, Himani Chandra2, Takako Araki1, Matthew V Potenza3, Maria Skamagas41Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA; 2Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, Jam...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Via MA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Bromocriptine Dopamine Agonists Diabetes Glycemic Control Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/cb1201f357514f8c890611a7afef052d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb1201f357514f8c890611a7afef052d
record_format	dspace
spelling	oai:doaj.org-article:cb1201f357514f8c890611a7afef052d2021-12-02T00:27:37ZBromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes1178-7007https://doaj.org/article/cb1201f357514f8c890611a7afef052d2010-03-01T00:00:00Zhttps://www.dovepress.com/bromocriptine-approved-as-the-first-medication-to-target-dopamine-acti-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Michael A Via1, Himani Chandra2, Takako Araki1, Matthew V Potenza3, Maria Skamagas41Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA; 2Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, James J Peters VA Medical Center, New York, NY, USA; 3Diabetes and Endocrinology, West Nyack, New York, NY, USA; 4Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY, USAAbstract: Type 2 diabetes mellitus (T2DM) continues to rise in prevalence in the United States and worldwide. Despite advances in medical treatments for T2DM, many patients remain uncontrolled. By targeting centrally mediated pathways of glucose metabolism, bromocriptine represents a novel therapeutic option in T2DM. Several small clinical trials demonstrate improvements in insulin resistance and glycemic control. After the submission of data from four recent, large clinical trials, the US Food and Drug Administration has approved the use of bromocriptine in T2DM. We review the available data from these four trials and other published studies. Bromocriptine is a promising therapy for diabetes patients and demonstrates modest improvements in glycemic control.Keywords: bromocriptine, dopamine agonists, diabetes, glycemic controlVia MADove Medical PressarticleBromocriptineDopamine AgonistsDiabetesGlycemic ControlSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 43-48 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Bromocriptine Dopamine Agonists Diabetes Glycemic Control Specialties of internal medicine RC581-951
spellingShingle	Bromocriptine Dopamine Agonists Diabetes Glycemic Control Specialties of internal medicine RC581-951 Via MA Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
description	Michael A Via1, Himani Chandra2, Takako Araki1, Matthew V Potenza3, Maria Skamagas41Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA; 2Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, James J Peters VA Medical Center, New York, NY, USA; 3Diabetes and Endocrinology, West Nyack, New York, NY, USA; 4Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY, USAAbstract: Type 2 diabetes mellitus (T2DM) continues to rise in prevalence in the United States and worldwide. Despite advances in medical treatments for T2DM, many patients remain uncontrolled. By targeting centrally mediated pathways of glucose metabolism, bromocriptine represents a novel therapeutic option in T2DM. Several small clinical trials demonstrate improvements in insulin resistance and glycemic control. After the submission of data from four recent, large clinical trials, the US Food and Drug Administration has approved the use of bromocriptine in T2DM. We review the available data from these four trials and other published studies. Bromocriptine is a promising therapy for diabetes patients and demonstrates modest improvements in glycemic control.Keywords: bromocriptine, dopamine agonists, diabetes, glycemic control
format	article
author	Via MA
author_facet	Via MA
author_sort	Via MA
title	Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
title_short	Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
title_full	Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
title_fullStr	Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
title_full_unstemmed	Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
title_sort	bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/cb1201f357514f8c890611a7afef052d
work_keys_str_mv	AT viama bromocriptineapprovedasthefirstmedicationtotargetdopamineactivitytoimproveglycemiccontrolinpatientswithtype2diabetes
_version_	1718403767028678656

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

Ejemplares similares